Dear APA 2023 Attendee –
In recent years great efforts have been made to give healthcare professionals more options to help improve the mental health of patients. With mental health conditions increasing worldwide, the need for innovation has become critical. After seven years of developing Prism for PTSD under the radar, and having just received FDA approval, the GrayMatters Health (GMH) team will demo the device and I invite you to see it in action at our booth (#352).
Augmenting overall treatment outcomes for psychotherapy and pharmacology, Prism for PTSD brings a third option to patients, empowering them to regain control over brain activity associated with PTSD. Prism for PTSD is a prescription non-invasive adjunct therapy that utilizes a proprietary amygdala-based biomarker, named EFP (EEG-fMRI-Pattern), to guide treatment, taking neurofeedback to the next level:
· Overall Treatment Improvement: Prism for PTSD has been shown to improve overall treatment efficacy, with no severe side effects. It has also shown a high level of acceptance by patients with low attrition.
· Cutting-Edge Technology: Prism for PTSD utilizes the amygdala-based EFP biomarker to help patients gain visibility into their brain activity in response to stimuli. During each session, patients are presented with avatars on a screen who are huddling around a nursing station, shouting. Patients are instructed to find a technique - a personal memory, emotion, or experience – to get the avatars to sit down and lower their voices. As patients utilize different mental strategies, Prism for PTSD conducts neurofeedback on the amygdala-based-EFP and adapts the scene accordingly.
· Giving Patients Agency: Like placing a mirror in front of a patient’s brain activity, Prism for PTSD helps patients take an active role in their treatment. Giving patients visibility into their amygdala’s response to stimuli, Prism for PTSD helps patients practice skills they develop and train themselves to regain control over brain activity associated with PTSD that can be utilized outside of the treatment setting.
· Fitted for Every Clinic: Prism is a prescription device, designed with operational simplicity to fit any mental healthcare clinic and can be operated by non-MDs under the direction of a psychologist or psychiatrist. It requires minimal training, using only EEG, and does not require an fMRI scan.
· Availability: Prism for PTSD is available for commercial use in select clinics. The company is in discussions with major US payors to support market adoption. Looking ahead, GMH has plans to evaluate Prism for treating additional mental disorders beyond PTSD.
If you’d like to learn more, I’d love to introduce you to Professor Talma Hendler, MD, PhD, the inventor of the technology, and the rest of the GMH team at our booth #352. You can also contact me directly via email (oded@graymatters.health) and schedule a time to meet.
I look forward to connecting!
Sincerely,
Oded Kraft CEO, GrayMatters Health